Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.

Similar Items

• Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
  by: Chien-Hung Gow, et al.
  Published: (2005-09-01)
• Combination of gefitinib and AZD6244 overcomes acquired gefitinib resistance and enhances anticancer effect in lung adenocarcinoma cells harboring an activating EGFR mutation
  by: Ya-Ju Chuang, et al.
  Published: (2011)
• Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
  by: William Pao, et al.
  Published: (2005-03-01)
• Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
  by: Taiji Kuwata, et al.
  Published: (2016-10-01)
• The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
  by: Chih-Jen Yang, et al.
  Published: (2017-05-01)